Home Newsfeeds Goldman Sachs Maintains Neutral on Belden, Raises Price Target to $76

Goldman Sachs Maintains Neutral on Belden, Raises Price Target to $76

Goldman Sachs analyst Mark Delaney maintains Belden (NYSE:BDC) with a Neutral and raises the price target from $67 to $76.

byBenzinga Newsdesk

November 3, 2022

1 minute read

Goldman Sachs analyst Mark Delaney maintains Belden (NYSE:BDC) with a Neutral and raises the price target from $67 to $76.

Healthy Demand For Home-Based Care Products Propel Healthcare Logistics Firm Owens & Minor’s Q4 Performance

By Vandana Singh

February 20, 2:00 PM

Owens & Minor's Q4 adjusted EPS soaring to $0.69, 4% Y/Y revenue growth to $2.66 billion, and robust Patient Direct revenue of $664 million.

OMI

$1000 Invested In Texas Instruments 15 Years Ago Would Be Worth This Much Today

By Benzinga Insights

September 20, 1:36 PM

Texas Instruments (NASDAQ:TXN) has outperformed the market over the past 15 years by 4.3% on an annualized basis producing an average annual return of 10.64%. Currently, Texas Instruments has a market capitalization of $151.23 billion.

TXN

NeuroMetrix Announces Review Of Strategic Options To Promote Growth Of Its Quell Neuromodulation And DPNCheck Neurodiagnostic Businesses And To Maximize Shareholder Value

By Benzinga Newsdesk

February 13, 10:03 AM

NeuroMetrix, Inc. (NASDAQ:NURO), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices, today announced a

NURO